PL EN


Preferences help
enabled [disable] Abstract
Number of results
2011 | 83 | 1 | 42-47
Article title

Evaluation of Endostatin and EGF Serum Levels in Patients with Gastric Cancer

Content
Title variants
Languages of publication
EN
Abstracts
EN
The aim of the study was to assess angiogenesis markers - endostatin and endothelial growth factor (EGF) as markers of detection of gastric carcinoma.Material and methods. The study involved 20 patients with colorectal cancer (10 women, 10 men) aged 35 - 75 years, mean age = 55 years ± 11.2 who referred to the 2nd Department of General Surgery, Medical University in Lublin between June 2008 and June 2009. The control group comprised 10 volunteers (6 women, 4 men) who underwent upper gastrointestinal (GI) endoscopy due to the reflux disease and in whom gastric cancer was not diagnosed.Results. The mean endostatin concentration in controls was 5.21 ng/mL ± 1.37. Mean concentrations in patients with gastric cancer were higher than those in controls - 5.91 ng/mL ± 1.5. The difference was not statistically significant (p= 0.714). The EGF concentration in the control group was 28.19 pg/mL ± 12.94. EGF concentrations in patients with gastric cancer were higher compared to the control group - 28.8 pg/mL ± 12.63. The difference was not statistically significant (p= 0.85). The mean concentration of endostatin before the operation was 5.91 ng/mL ± 1.5 and after surgery was 5.33 ng/mL ± 2.01, the difference was not statistically significant.Conclusions. Blood endostatin and EGF quantitative determinations probably is not useful for detection of gastric carcinoma and effectiveness of treatment.
Publisher

Year
Volume
83
Issue
1
Pages
42-47
Physical description
Dates
published
1 - 1 - 2011
online
14 - 3 - 2011
Contributors
  • 2nd Department of General Surgery, Medical University in Lublin
author
  • Dermatology Department, Medical University in Lublin
  • Dermatology Department, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin
  • 2nd Department of General Surgery, Medical University in Lublin
References
  • National Cancer Institute, U. S. National Institutes of Health; (online) (dostęp 1 listopada 2010), baza internetowa:
  • Krajowy Rejestr Nowotworów; (online) (dostęp 1 listopada 2010), baza internetowa:
  • Biuletyn Statystyczny Ministerstwa Zdrowia 2007. Centrum Systemów Informacyjnych Ochrony Zdrowia 2007; 10-11.
  • Wallner G, Ciechański A, Dąbrowski A et al.: Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer. Folia Histochem Cytobiol 2001; 39, 2: 122-23.[PubMed]
  • Ren B, Höti N, Rabasseda X et al.: The antiangiogenic and therapeutic implications of endostatin. Methods Find Exp Clin Pharmacol 2003; 25: 215-24.[PubMed][Crossref]
  • O'Reilly MS, Boehm T, Shing Y et al.: Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth. Cell 1997; 88: 277-86.[Crossref]
  • Kisker O, Becker CM, Prox D et al.: Continuous Administration of Endostatin by Intraperitoneally Implanted Osmotic Pump Improves the Efficacy and Potency of Therapy in a Mouse Xenograft Tumor Model. Cancer Res 2001; 61: 7669-74.
  • Eisterer W, Jiang X, Bachelot T et al.: Unfulfilled Promise of Endostatin in a Gene Therapy-Xenotransplant Model of Human Acute Lymphocytic Leukemia. Mol Ther 2002; 5: 352-59.[Crossref]
  • Cohen S: Purification of a nerve-growth promoting protein from the mouse salivary gland and its neuro-cytotoxic antiserum. Proc Natl Acad Sci USA 1960; 46: 302-11.[Crossref]
  • Levi-Montalcini R, Cohen S: Effects of the extract of the mouse submaxillary salivary glands on the sympathetic system of mammals. Ann N Y Acad Sci 1960; 85: 324-41.
  • Massague J: Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem 1990; 263: 21393-96.
  • Gross ME, Zorbas MA, Danels YJ et al.: Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 1991; 51:1452-59.[PubMed]
  • Radinsky R, Risin S, Fan D et al.: Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1: 19-31.[PubMed]
  • Messa C, Russo F, Caruso MG et al.: EGF, TGF-alpha, and EGFR-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37: 285-89.
  • Mayer A, Takimoto M, Fritz E: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993; 71: 2454-60.[PubMed][Crossref]
  • Kluftinger AM, Robinson BW, Quenville NF: Correlation of epidermal growth factor receptor and cerbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1992; 1: 97-105.[Crossref]
  • Kuroi K, Tanaka C, Toi M: Circulating levels of endostatin in cancer patients. Oncol Rep 2001; 8:405-09.[PubMed]
  • Shaarawy M, El-Sharkawy SA: Biomarkers of Intrinsic Angiogenic and Anti-angiogenic Activity in Patients with Endometrial Hyperplasia and Endometrial Cancer. Acta Oncol 2001; 40: 513.[Crossref][PubMed]
  • Glengen N, Mosevoll KA, Bruserud O et al.: Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chomiotherapy for acute myelogenous leukemia. Int J Cancer 2002; 101: 86-94.[Crossref]
  • Hata, K, Kumar Dhar D, Kanasaki H et al.: Serum endostatin levels in patients with epithelial ovarian cancer. Anticancer Res 2003; 23:1907-12.[PubMed]
  • Suzuki M, Iizasa T, Ko E et al.: Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer 2002; 35: 29-34.[PubMed][Crossref]
  • Dhar DK, Ono T, Yamanoi A et al.: Serum Endostatin Predicts Tumor Vascularity In Hepatocellular Carcinoma. Cancer 2002; 95: 2188-95.[Crossref][PubMed]
  • Homer JJ, Greenman J, Stafford ND: Circulating angiogenic cytokines as tumour markers and prognostic factors in head and neck squamous cell carcinoma. Clin Otolaryngol 2002; 27: 32-37.[Crossref]
  • Öhlund D, Ardnor B, Öman M et al.: Expression pattern and circulating levels of endostatin in patients with pancreas cancer. Int J Cancer 2008; 122: 2805-10.[Crossref]
  • Hedayati M, Kołomecki K, Pasieka Z i wsp.: Ocena stężeń naczyniowo-śródbłonkowego czynnika wzrostu oraz endostatyny w surowicy krwi chorych z łagodnymi i złośliwymi guzami tarczycy. Onkol Pol 2005; 8, 1: 7-12.
  • Wróbel T, Mazur G, Kapelko K et al.: Endostatin serum level in acute myeloid leukemia. Neoplasma 2005; 52, 2: 182-84.[PubMed]
  • Tomaszewski J, Miturski R, Kotarski J: Concentration of epidermal growth factor (EGF) in serum of women with endometrial cancer. Gin Pol 1996; 67: 248-53.
  • Konturek A, Barczyński M, Cichoń S et al.: Significance of vascular endothelial growth factor and epidermal growth factor in development of papillary thyroid cancer Langenbeck's. Arch Surg 2005; 390, 3: 216-21.
  • Pawlikowski M, Cieslak D, Stepien H et al.: Elevated blood serum levels of epidermal growth factor in some patients with gastric cancer. Endokrynol Pol 1989; 40: 149-53.[PubMed]
  • Wang Y, Tian T, Hu Z et al.: EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women. Breast Cancer Res Treat 2008; 111: 321-27.[PubMed][WoS][Crossref]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_v10035-011-0006-8
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.